Drug Profile


Alternative Names: GSK 2696266; RSC 649266; S 649266

Latest Information Update: 16 Jan 2017

Price : $50

At a glance

  • Originator Shionogi
  • Class Antibacterials; Cephalosporins
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Gram-negative infections

Most Recent Events

  • 12 Jan 2017 Shionogi announces intention to submit NDA to FDA in 2017
  • 12 Jan 2017 Efficacy and adverse events data from a phase II trial in Gram negative infections released by Shionogi
  • 12 Jan 2017 Shionogi completes a phase II trial in Gram negative infections in USA, Bulgaria, Croatia, Czech Republic, Georgia, Germany, Hungary, Italy, Japan, Latvia, Poland, Romania, Russia and Spain (NCT02321800)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top